期刊文献+

Bcl-2反义寡核苷酸增强K562细胞对依托泊苷化疗敏感性的研究

Effect of Bcl-2 Antisense Oligonucleotide on Chemotherapy Sensitivity of Etoposide in Cell Line K562
下载PDF
导出
摘要 目的探讨Bcl-2反义寡核苷酸能否增强K562细胞对依托泊苷的化疗敏感性。方法采用人工方法合成Bcl-2寡核苷酸,通过脂质体将Bcl-2不同寡核苷酸导入K562细胞中(正义寡核苷酸组、无义寡核苷酸组、反义寡核苷酸组),另设未经转染空白对照组,检测Bcl-2蛋白的表达和细胞凋亡率。采用不同浓度的依托泊苷作用于4组细胞,用MTT法测定细胞存活分数。结果空白对照组和正义、无义寡核苷酸组的K562细胞Bcl-2蛋白与Bcl-2蛋白条带相符,反义寡核苷酸组在相应位置未见蛋白条带,且凋亡率显著高于其他3组(P<0.01)。细胞与依托泊苷作用后,反义寡核苷酸组细胞在各个浓度的存活分数均低于其他3组(P<0.05)。结论 Bcl-2反义寡核苷酸能有效封闭Bcl-2基因表达,增加K562细胞的凋亡,增强依托泊苷的敏感性。 Objective To study the effect of Bcl-2 antisense oligonucleotide on chemotherapy sensitivity of Etoposide in cell line K562.Methods Different oligonucleotides were introduced into cultured K562 cells: antisense oligonucleotide group(ASODN group),sense oligonucleotide group(SODN group),non-sense oligonucleotide(NSODN group),and blank control group without trasfection was established.The Bcl-2 protein and apoptosis rate were detected.After the 4 groups were treated by different concentrations of Etoposide,cell survival rate was detected by MTT.Results The expression of Bcl-2 protein blank control group,SODN group and NSODN group showed the same strap as Bcl-2 protein,but it was not found in ASODN group.Apoptosis rate in ASODN group was higher than that in the other 3 groups(P〈0.01).After being treated with different concentrations of Etoposide,cell survival rate in NSODN group was lower than that in the other 3 groups(P〈0.05).Conclusion The Bcl-2 antisense oligonucleotide can close the expression of Bcl-2 gene,increase the apoptosis of K562 cell line and enhance the sensitivity of etoposide.
作者 张彦 孙红
出处 《临床误诊误治》 2011年第9期4-6,F0003,共4页 Clinical Misdiagnosis & Mistherapy
关键词 基因 BCL-2 寡核苷酸类 反义 K562细胞 依托泊苷 Gene Bcl-2 Antisense oligonucleotide K562 cell line Etoposide
  • 相关文献

参考文献10

  • 1Jin Z, El Deiry W S. Overview of cell death signaling path- ways[J]. Cancer Biol Ther, 2005,4(2) 139-163.
  • 2Tothova E, Fricova M, Stecova N, et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy [J]. Neoplasma, 2002,49 (3) :141-144.
  • 3Tsujmoto Y, Gorham J , Cossman J, et al. The t (14;18) chromosome translocations involved in B-cell neoplasms re- sult from mistakes in VDJ joining [ J ]. Science, 1985,229 (4720) : 1390-1393.
  • 4Huang Z. Bcl-2 family proteins as targets for anticancer drug design [ J ]. Oncogene, 2000,19 ( 56 ) :6627-6631.
  • 5Gjertsen B T, Bredholt T, Anensen N, et al. Bcl-2 antisense in the treatment of human malignancies: a delusion in targe- ted therapy[J]. Curr Pharn Biotechnol, 2007,8(6) :373-381.
  • 6雷小勇,张洹,何冬梅.Bcl-2反义核酸的设计及对K562细胞凋亡的研究[J].临床血液学杂志,2002,15(6):248-250. 被引量:5
  • 7Marcucci G, Byrd J C, Dai G, et al. Phase 1 and pharmaco- dynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed a- cute leukemia[J]. Blood, 2003,101 (2) :425-432.
  • 8Marcucci G, Stock W, Dai G, et al. PhaseIstudy of oblim- ersen sodium, an antisense to Bcl -2, in untreated older pa- tients with acute myeloid leukemia: pharmacokinetics, phar- macodynemics, and clinical activity[ J]. J Clin Oncol, 2005, 23 ( 15 ) :3404-3411.
  • 9Sezgedi I, Katona K, Horvath A, et al. Bcl-2 antisense oli- gonucleotide inhibits the proliferation of childhood leukemia/ lymphoma ceils of the B-cell lineage [ J ]. Pathol Oncol Res, 2008,14(3 ) :275-279.
  • 10Smith S. Anti Bcl-2 therapy in chronic myelogenous leukemi- a[J]. Leuk Lymphoma, 2008,49(7) :1232-1233.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部